Does the intragastric balloon have a predictive role in subsequent LAP-BAND® surgery? Italian multicenter study results at 5-year follow-up

Genco, Alfredo; Lorenzo, Michele; Baglìo, Giovanni; Furbetta, Francesco; Rossi, Angelo; Lucchese, Marcello; Zappa, Marco Antonio; Giardiello, Cristiano; Micheletto, Giancarlo; Bottari, Giorgio; Puglisi, Francesco; Montanari, Luca; Civitelli, Simona; Forestieri, Pietro

doi:10.1016/j.soard.2013.10.021

Cited by 26 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our department, the IGB is also used to treat patients who have contraindications for surgical treatment. It is frequently utilized prior to surgery as a bridge therapy, to achieve a better therapeutic effect [ 4 , 9 – 11 ]. Optimal therapy outcomes are typically achieved in patients with BMI of 30 mg/kg 2 to 40 mg/kg 2 [ 12 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…Among various approaches to treating obesity, endoscopic methods are used in selected cases, including endoscopically placed intragastric balloons (IGBs). The IGB therapy is used as a bridge to definitive treatment, to facilitate weight loss and optimal patient management prior to bariatric surgery [ 4 , 5 ]. Also, it is used to treat extremely obese patients with multiple comorbidities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanical intestinal obstruction caused by displacement of a stomach balloon - case report.

Twardzik

Wiewióra

Glück

et al. 2018

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

Methods of treating obesity in selected cases include endoscopically performed procedures, among them endoscopically placed intragastric balloons. It is a method associated with a low complication rate, traditionally reserved to treat the most obese patients. Balloon rupture or deflation and its migration into the small bowel is one of the possible complications. In some cases, the balloon moves through the digestive tract without side effects. When the balloon’s displacement in the intestine is impossible, gastrointestinal obstruction occurs. We report a case of a patient with a mechanical obstruction of the gastrointestinal tract caused by asymptomatic balloon rupture and its migration into the jejunum.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mechanical intestinal obstruction caused by displacement of a stomach balloon - case report.

Twardzik

Wiewióra

Glück

et al. 2018

Videosurgery and Other Miniinvasive Techniques

View full text Add to dashboard Cite

show abstract

“…To date, the largest European experience on ORBERA ® was published in 2005 by the Italian LAP-BAND ® and BIB ® group (GILB). In this clinical trial, accounting for 2515 patients with a mean initial BMI of 44.4 kg/m 2 and a mean excess weight of 59.5 kg, %EWL was 33.9% after the 6-month IGB treatment [18].…”

Section: Orbera ® Intragastric Balloon Systemmentioning

confidence: 97%

Intragastric Occupying Space Devices

Genco

Ernesti

Gualtieri

2020

Gastrointestinal and Pancreatico-Biliary Diseases: Advanced Diagnostic and Therapeutic Endoscopy

Self Cite

View full text Add to dashboard Cite

In 2016, 39% of adults were overweight, and about 13% of the world's adult population were obese. Obesity represents a growing global public health despite the availability of diet and lifestyle counseling, pharmacologic therapy, and bariatric surgery. Endoscopic bariatric therapies (EBTs) encompass a wide range of devices requiring flexible endoscopy for placement or removal and procedures performed via flexible endoscopy for the treatment of obesity. Current primary EBTs can be classified as space-occupying or non-space-occupying devices (restrictive, bypass, or aspiration therapy).Intragastric balloons (IBG) act as space-occupying devices, reducing stomach capacity and inducing satiety by several mechanisms. To date, ORBERA ® Intragastric Balloon System, RESHAPE DUO Intragastric Balloon, and OBALON Balloon System are approved by the US Food and Drug Administration (FDA) based on demonstrated safety and efficacy in randomized controlled trials (RCTs). Two other balloons are currently under FDA investigation: the

show abstract

“…He was the first surgeon to start bariatric surgery in Southern Italy and was one of the founders of the Italian Group for the Study of the Lap Band and the Intragastric Balloon (GILB) in 1999. The data collected by GILB have helped the Italian medical community to accept surgery as an effective treatment for obesity [1,2].…”

mentioning

confidence: 99%

Biography of Professor Pietro Forestieri, Honorary President of the Italian Society for the Surgery of Obesity (SICOB)

Pilone,

Vitiello

2024

OBES SURG

View full text Add to dashboard Cite

Does the intragastric balloon have a predictive role in subsequent LAP-BAND® surgery? Italian multicenter study results at 5-year follow-up

Cited by 26 publications

References 24 publications

Mechanical intestinal obstruction caused by displacement of a stomach balloon - case report.

Mechanical intestinal obstruction caused by displacement of a stomach balloon - case report.

Intragastric Occupying Space Devices

Biography of Professor Pietro Forestieri, Honorary President of the Italian Society for the Surgery of Obesity (SICOB)

Contact Info

Product

Resources

About